Ligand Pharmaceuticals LGND Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's other accrued liabilities?
- Ligand Pharmaceuticals (LGND) reported other accrued liabilities of $1.12M in Q1 2026.
- How has Ligand Pharmaceuticals's other accrued liabilities changed year-over-year?
- Ligand Pharmaceuticals's other accrued liabilities increased by 80.4% year-over-year, from $622K to $1.12M.
- What is the long-term trend for Ligand Pharmaceuticals's other accrued liabilities?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's other accrued liabilities has grown at a -17.1% compound annual growth rate (CAGR), from $3.64M to $1.43M.